ETF Holdings Breakdown of BCYC

Stock Name	Bicycle Therapeutics Ltd
Ticker	BCYC(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US0887861088

BCYC institutional holdings

The adjusted close for BCYC on 2025-11-11 was 6.83

The following institutional investment holdings of BCYC have been identified

Date ETF ISIN/Name Num Shares Book value Derived Price per Share Comment
2025-11-11 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 30,460 USD 208,042 3.7% 6.83

2025-11-11 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 30,460 USD 208,042 3.7% 6.83

Total = 60,920 USD 416,084
Book value of shares is calculated on the adjusted close price of each day (row).

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share
2025-11-11	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	30,460	USD 208,042 3.7%	6.83
2025-11-11	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	30,460	USD 208,042 3.7%	6.83
Total =	60,920	USD 416,084

News associated with BCYC

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Recommendation of “Moderate Buy” from Analysts: Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the ten ratings firms that are covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average […] - 2025-07-29 02:14:55
Principal Financial Group Inc. Grows Stake in Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC): Principal Financial Group Inc. lifted its holdings in Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC – Free Report) by 55.3% in the first quarter, Holdings Channel reports. The firm owned 631,260 shares of the company’s stock after buying an additional 224,790 shares during the period. Principal Financial Group Inc.’s holdings in Bicycle Therapeutics were worth $5,359,000 […] - 2025-07-17 04:35:03
Analyzing Bicycle Therapeutics (NASDAQ:BCYC) & Galecto (NASDAQ:GLTO): Galecto (NASDAQ:GLTO – Get Free Report) and Bicycle Therapeutics (NASDAQ:BCYC – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends. Profitability This table compares Galecto and Bicycle Therapeutics’ […] - 2025-07-15 06:24:40
Kevin Lee Sells 3,193 Shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Stock: Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC – Get Free Report) CEO Kevin Lee sold 3,193 shares of the company’s stock in a transaction dated Thursday, July 3rd. The shares were sold at an average price of $7.44, for a total transaction of $23,755.92. Following the transaction, the chief executive officer owned 480,804 shares in the […] - 2025-07-09 07:17:05
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives $25.00 Consensus PT from Analysts: Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC – Get Free Report) has received an average recommendation of “Moderate Buy” from the ten ratings firms that are presently covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average […] - 2025-07-07 02:32:44
Bicycle Therapeutics plc (NASDAQ:BCYC) Stock Holdings Raised by Harbor Capital Advisors Inc.: Harbor Capital Advisors Inc. raised its stake in Bicycle Therapeutics plc (NASDAQ:BCYC – Free Report) by 12.6% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 148,129 shares of the company’s stock after purchasing an additional 16,624 shares during the period. Harbor Capital Advisors Inc.’s holdings in Bicycle […] - 2025-06-13 05:18:56
Bicycle Therapeutics plc (NASDAQ:BCYC) Receives $25.00 Consensus Price Target from Analysts: Bicycle Therapeutics plc (NASDAQ:BCYC – Get Free Report) has been given an average rating of “Moderate Buy” by the ten research firms that are presently covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1 […] - 2025-06-12 02:29:00
Deutsche Bank AG Sells 1,653 Shares of Bicycle Therapeutics plc (NASDAQ:BCYC): Deutsche Bank AG cut its stake in Bicycle Therapeutics plc (NASDAQ:BCYC – Free Report) by 20.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,417 shares of the company’s stock after selling 1,653 shares during the period. Deutsche Bank […] - 2025-06-04 04:54:43
Bicycle Therapeutics plc (NASDAQ:BCYC) Given Average Rating of “Moderate Buy” by Analysts: Bicycle Therapeutics plc (NASDAQ:BCYC – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the ten brokerages that are currently covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12 month price objective […] - 2025-05-15 02:52:49
Legal & General Group Plc Decreases Stake in Bicycle Therapeutics plc (NASDAQ:BCYC): Legal & General Group Plc lessened its position in Bicycle Therapeutics plc (NASDAQ:BCYC – Free Report) by 41.8% during the fourth quarter, Holdings Channel.com reports. The fund owned 139,075 shares of the company’s stock after selling 99,741 shares during the period. Legal & General Group Plc’s holdings in Bicycle Therapeutics were worth $1,947,000 at the […] - 2025-04-25 05:13:07
Renaissance Technologies LLC Decreases Position in Bicycle Therapeutics plc (NASDAQ:BCYC): Renaissance Technologies LLC cut its stake in shares of Bicycle Therapeutics plc (NASDAQ:BCYC – Free Report) by 1.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 269,500 shares of the company’s stock after selling 3,100 shares during the quarter. Renaissance Technologies LLC’s holdings […] - 2025-04-23 05:27:02
Bicycle Therapeutics plc (NASDAQ:BCYC) Receives $29.14 Consensus PT from Brokerages: Shares of Bicycle Therapeutics plc (NASDAQ:BCYC – Get Free Report) have earned an average recommendation of “Moderate Buy” from the eight brokerages that are covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1-year price […] - 2025-04-23 02:30:48
Needham & Company LLC Reaffirms “Buy” Rating for Bicycle Therapeutics (NASDAQ:BCYC): Needham & Company LLC reiterated their buy rating on shares of Bicycle Therapeutics (NASDAQ:BCYC – Free Report) in a research note issued to investors on Tuesday morning,Benzinga reports. The brokerage currently has a $30.00 price objective on the stock. BCYC has been the subject of several other reports. Stephens reissued an “equal weight” rating and […] - 2025-03-12 04:58:43

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.